Journal of Antimicrobial Chemotherapy (2002) 50, 349-360
© 2002 The British Society for Antimicrobial Chemotherapy
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones
Service des Maladies Infectieuses, Microbiologie Médicale et Moléculaire (EA562), Hôpital du Bocage, BP 1542, 21034 Dijon Cedex, France
Received 4 February 2002; returned 29 April 2002; revised 15 May 2002; accepted 30 May 2002
Newer fluoroquinolones, such as levofloxacin, have shown an enhanced in vitro and in vivo activity against penicillin-resistant Streptococcus pneumoniae infections. The frequency of S. pneumoniae with reduced susceptibility to quinolones, although currently low, raises the question of the therapeutic efficacy of levofloxacin on infection due to such strains. We used an animal model of penicillin-resistant pneumococcal pneumonia using six strains with various levels of susceptibility to ciprofloxacin and levofloxacin in rabbits to induce pneumonia, and simulated a human-like treatment of 500 mg twice a day for 48 h. Strains’ susceptibility profiles for ciprofloxacin and levofloxaxin were (ciprofloxacin/levofloxacin MIC, mg/L; genotype): 0.5/0.5 (Cip0.5), 2/1 (Cip2), 4/1.75 (Cip4), 8/1.75 (parC mutation) (Cip8), 10/2 (parC mutation) (Cip10), 64/16 (parC and gyrA mutations) (Cip64), respectively. All the strains induced a crude pneumonia in all rabbits. Significant bacterial reductions at the end of treatment in lung and spleen were observed for the four former strains (P < 0.05) but not for the latter two. An AUC/MIC ratio of at least 32 identified 95% of an at least bacteriostatic effect (P = 0.038) and 76% of a bactericidal effect (P = 0.09). Mutants were detected in treated animals infected with strains harbouring parC mutations (Cip8 and Cip10) and when the AUC/MIC ratio was between 13 and 31. We conclude that levofloxacin is effective against experimental pneumonia due to pneumococci with MIC < 1.5 mg/L, ineffective on experimental pneumonia due to pneumococci with MIC 
2 mg/L, and could be associated with the appearance of mutants when a parC mutation is pre-existing.
* Corresponding author. Tel: +33-3-8029-3637; Fax: +33-3-8029-3638; E-mail: p.chavanet{at}planetb.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Chiavolini, G. Pozzi, and S. Ricci Animal Models of Streptococcus pneumoniae Disease Clin. Microbiol. Rev., October 1, 2008; 21(4): 666 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DeRyke, X. Du, and D. P. Nicolau Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae J. Antimicrob. Chemother., September 1, 2006; 58(3): 601 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Decousser, I. Methlouthi, P. Pina, A. Collignon, P. Allouch, and on behalf of the ColBVH Study Group New Real-Time PCR Assay Using Locked Nucleic Acid Probes To Assess Prevalence of ParC Mutations in Fluoroquinolone-Susceptible Streptococcus pneumoniae Isolates from France. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1594 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Croisier, M. Etienne, L. Piroth, E. Bergoin, C. Lequeu, H. Portier, and P. Chavanet In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants J. Antimicrob. Chemother., September 1, 2004; 54(3): 640 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Croisier, M. Etienne, E. Bergoin, P.-E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1699 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Florea, P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1215 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rubinstein Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones J. Antimicrob. Chemother., May 1, 2003; 51(5): 1307 - 1308. [Full Text] [PDF]
|
|